Pancreatic Disorders News

Johns Hopkins Kimmel Cancer Center researchers have developed a blood test designed to screen for the eight most common cancer types.

Herbert J. Zeh, III, has been chosen as the next chair of the department of surgery at UT Southwestern.

A randomized clinical trial is underway to assess the efficacy of the novel immunotherapy durvalumab as maintenance therapy for patients with pancreatic cancer.

Anthera Pharmaceuticals announced it will discontinue the development of Sollpura after the drug failed to meet the primary endpoint of a phase 3 trial.

Boston Scientific announced that it has acquired EMcision, a company based in the United Kingdom and Canada.

Paul E. Oberstein, MD, has been appointed director of gastrointestinal medical oncology at NYU Langone Health and its Perlmutter Cancer Center.

The FDA granted fast track designation to pamrevlumab for the treatment of patients with locally advanced unresectable pancreatic cancer, according to a manufacturer-issued press release.

The Stand Up To Cancer foundation has formed a “dream team” to identify new ways to detect pancreatic cancer at earlier stages when it is most amenable to treatment.

The American College of Gastroenterology has released new guidelines on the diagnosis and management of pancreatic cysts.

The FDA granted orphan drug designation to YS-ON-001, an immuno-oncology biologic product, for the treatment of pancreatic cancer, according to the agent’s manufacturer.